HWHugh Welch

Hugh Welch

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hugh Welch has a total of 91 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Indwelling pleural catheters with talc pleurodesis for recurrent heart failure-related pleural effusions: The REDUCE-2 feasibility randomised trial

    by Hugh Welch, Emma Tucker, Avinash Aujayeb, Kevin Conroy, Thapas Nagarajan, Rakesh Panchal, Geraldine Lynch, Alina Ionescu, Owais Kadwani, John Corcoran, et al.

    Background: Heart failure is the most common cause of pleural effusions. For patients with refractory HF-related pleural effusions (HFPE), repeated therapeutic thoracentesis (TT) is standard care. In malignant pleural effusions, indwelling pleural catheters (IPCs) combined with talc instillation improve pleurodesis rates, but their role in HFPE remains uncertain. Aims: To evaluate the feasibility of conducting a full-scale multicentre randomised trial comparing recurrent TT with IPC insertion, daily drainage, and talc instillation across 13 UK centres. Feasibility was defined a priori as achieving 80% of the target sample size (40 patients) and enrolling ≥50% of eligible patients. Methods: Adults with refractory HFPE were assessed for eligibility and randomised 1:1 to TT or IPC with daily drainage and talc. The trial was non-blinded, and participants were followed for 12 weeks. Results: Among 231 patients screened, 43 were eligible; most exclusions reflected insufficient effusion size or symptom severity, or improvement following medical optimisation. Eighteen patients (42% of those eligible) were randomised (median age 79; IQR 70–83; Clinical Frailty Score 6; IQR 5–6). Eight participants completed follow-up; five died, and five withdrew. Pleurodesis occurred in 3/8 (38%) in the IPC/talc arm and in none of the TT arm. The IPC/talc arm required fewer total pleural procedures (1.0 versus 2.0; p<0.001) but experienced a higher complication rate. Conclusions: Feasibility targets were not met. Improvements in medical management may have reduced the need for invasive treatment of HFPE, with many screened patients responding to medical therapy alone. Further challenges to recruitment included the elderly, polymorbid and frail nature of the cohort.

  • Open Access

    Characteristics and predictors of clinical outcome in patients with pleural effusions caused by heart, liver and renal failure: results from the ERS International Multicentre Pleural Research Collaborative (IMPACT) registry

    by Hugh Welch, Steven Walker, Jordy Kerkhoff, Julius Janssen, Silvia Bielsa, Carmen Civit, Jose M. Porcel, Katrine Fjaellegaard, Jesper Petersen, Uffe Bodtger, et al.

    Introduction: Pleural effusions caused by organ dysfunction are the commonest pleural disease and account for a huge healthcare burden. Previous work has demonstrated poor survival rates, but there is still uncertainty about determinants of prognosis. This study describes the characteristics and risk factors for poor outcomes in patients with pleural effusion secondary to organ failure in an international cohort. Methods: The European Respiratory Society International Multicentre Pleural Research Collaborative (IMPACT) registry includes an international retrospective study of patients with effusions secondary to heart, liver or renal failure, collected from 10 countries in Europe and North and South America between 2019 and 2021. The data were analysed for associations between baseline patient characteristics and key clinical outcomes. Descriptive data were collected on treatments and complications. Results: A total of 755 patients contributed data. Overall, 85.2% of effusions were classified as transudates by Light's criteria. 42% of effusions were bilateral. One-year mortality rates were 46% in renal, 35% in hepatic and 33% in cardiac effusions. Increased mortality was observed in neutrophil-predominant effusions (HR 2.001, 95% CI 1.202–3.349, p=0.008), with age (HR 1.013, 95 CI 1.002–1.024, p=0.02) and with N-terminal pro-brain natriuretic peptide >450 pg·mL −1 (HR 1.508, 95% CI 1.191–1.911) in patients with cardiac failure. Therapeutic thoracentesis was the most frequently employed pleural intervention; indwelling pleural catheter use was rare and associated with higher pleural infection rates than thoracentesis. Conclusion: This study identifies prognostic factors in an international cohort of patients with transudative pleural effusions. Identification of these risk factors may support treatment approaches in a global population.


  • Top Cited Papers

    ERS statement on benign pleural effusions in adults

    by Anand Sundaralingam, Elzbieta M. Grabczak, Patrizia Burra, M. Inês Costa, Vineeth George, Eli Harriss, Ewa A. Jankowska, Julius P. Janssen, Georgia Karpathiou, Christian B. Laursen, et al.

    The incidence of non-malignant pleural effusions far outweighs that of malignant pleural effusions and is estimated to be at least 3-fold higher. These so-called benign effusions do not follow a “benign course” in many cases, with mortality rates matching and sometimes exceeding those of malignant pleural effusions. In addition to the impact on patients, healthcare systems are also significantly affected, with recent US epidemiological data demonstrating that 75% of resource allocation for pleural effusion management is spent on non-malignant pleural effusions (excluding empyema). Despite this significant burden of disease, and by existing at the junction of multiple medical specialties, reflecting a heterogenous constellation of medical conditions, non-malignant pleural effusions are rarely the focus of research or the subject of management guidelines. With this European Respiratory Society Task Force, we assembled a multispecialty collaborative across 11 countries and three continents to provide a statement based on systematic searches of the medical literature to highlight evidence in the management of the following clinical areas: a diagnostic approach to transudative effusions, heart failure, hepatic hydrothorax, end-stage renal failure, benign asbestos-related pleural effusion, post-surgical effusion and nonspecific pleuritis.


  • Open Access

    Clinical characteristics of chylothorax: results from the International Collaborative Effusion database

    by José M. Porcel, Silvia Bielsa, Carmen Civit, Avinash Aujayeb, Julius Janssen, Uffe Bodtger, Katrine Fjaellegaard, Jesper Koefod Petersen, Hugh Welch, Jenny Symonds, et al.

    Background: Chylothorax is an uncommon medical condition for which limited data are available regarding the contemporary aetiology, management and outcomes. The goal of this study was to better define these poorly characterised features.Methods: The medical records of adult patients diagnosed with chylothorax at 12 centres across Europe, America and South Africa from 2009–2021 were retrospectively reviewed. Descriptive and inferential statistics were performed.Results: 77 patients (median age 69 years, male to female ratio 1.5) were included. Subacute dyspnoea was the most typical presenting symptom (66%). The commonest cause of chylothorax was malignancy (68.8%), with lymphoma accounting for 62% of these cases. Other aetiologies were trauma (13%), inflammatory/miscellaneous conditions (11.7%) and idiopathic cases (6.5%). At the initial thoracentesis, the pleural fluid appeared milky in 73%, was exudative in 89% and exhibited triglyceride concentrations >100 mg·dL−1in 88%. Lymphangiography/lymphoscintigraphy were rarely ordered (3%), and demonstration of chylomicrons in pleural fluid was never ascertained. 67% of patients required interventional pleural procedures. Dietary measures were infrequently followed (36%). No patient underwent thoracic duct ligation or embolisation. Morbidity included infections (18%), and thrombosis in malignant aetiologies (16%). The 1-year mortality was 47%. Pleural fluid protein >3.5 mg·dL−1(sub-distribution hazard ratio (SHR) 4.346) or lactate dehydrogenase −1(SHR 10.21) increased the likelihood of effusion resolution. Pleural fluid protein ≤3.5 mg·dL−1(HR 4.047), bilateral effusions (HR 2.749) and a history of respiratory disease (HR 2.428) negatively influenced survival.Conclusion: Chylothoraces have a poor prognosis and most require pleural interventions. Despite the standard recommendations, lymphatic imaging is seldom used, nor are dietary restrictions followed.


  • Open Access

    Investigation and outcomes in patients with nonspecific pleuritis: results from the International Collaborative Effusion database

    by Anand Sundaralingam, Avinash Aujayeb, Karl A. Jackson, Emilia I. Pellas, Irfan I. Khan, Muhammad T. Chohan, Roos Joosten, Anton Boersma, Jordy Kerkhoff, Silvia Bielsa, et al.

    Introduction: We present findings from the International Collaborative Effusion database, a European Respiratory Society clinical research collaboration. Nonspecific pleuritis (NSP) is a broad term that describes chronic pleural inflammation. Various aetiologies lead to NSP, which poses a diagnostic challenge for clinicians. A significant proportion of patients with this finding eventually develop a malignant diagnosis.Methods: 12 sites across nine countries contributed anonymised data on 187 patients. 175 records were suitable for analysis.Results: The commonest aetiology for NSP was recorded as idiopathic (80 out of 175, 44%). This was followed by pleural infection (15%), benign asbestos disease (12%), malignancy (6%) and cardiac failure (6%). The malignant diagnoses were predominantly mesothelioma (six out of 175, 3.4%) and lung adenocarcinoma (four out of 175, 2.3%). The median time to malignant diagnosis was 12.2 months (range 0.8–32 months). There was a signal towards greater asbestos exposure in the malignant NSP group compared to the benign group (0.63versus0.27, p=0.07). Neither recurrence of effusion requiring further therapeutic intervention nor initial biopsy approach were associated with a false-negative biopsy. A computed tomography finding of a mass lesion was the only imaging feature to demonstrate a significant association (0.18versus0.01, p=0.02), although sonographic pleural thickening also suggested an association (0.27versus0.09, p=0.09).Discussion: This is the first multicentre study of NSP and its associated outcomes. While some of our findings are reflected by the established body of literature, other findings have highlighted important areas for future research, not previously studied in NSP.


  • Open Access

    O22: CONJUGATED IRON NANOPARTICLES AS THERAPEUTIC CARRIERS FOR SPECIFIC TARGETING OF CANCER CELLS

    by Ff Alfadli, R Sarwary, J Correia, B Ramesh, H Welch

    Precision medicine with minimal side effects remains the goal of cancer therapy. Iron oxide nanoparticles are non‐toxic, successful carriers of substances, targeting tissues and delivering high payloads of conjugated agents. Interfering RNA (siRNA) disrupts protein expression, an effective treatment e.g. for hereditary amyloidosis. This study tested transferrin‐conjugated dopamine‐coated iron oxide nanoparticle (TF‐dpFe3O4) delivery of siRNA to cells overexpressing transferrin receptor (TFR). Cells were cultured in FBS‐DMEM/F12. Fe3O4 nanoparticles were prepared by co‐precipitation, dopamine coated +/‐ transferrin conjugation. LDH/MTT assays assessed cell viability responses to [TF‐dpFe3O4] or [dpFe3O4]. Protein expression was examined by PAGE, densitometry and immunofluorescence. Targeting efficacy was determined by MEK2 gene silencing using siRNA‐conjugated TF‐dpFe3O4 or dpFe3O4. T‐47D cells expressed high levels of TFR and MEK2. No significant effect on cell viability was observed with ≤2.5mg/mL TF‐dpFe3O4 or dpFe3O4. By conventional transfection, 10nM siRNA lowered MEK2 expression levels to 25% (48hr); levels rebounded to 50% by 72hr. 10nM siRNA‐conjugated TF‐dpFe3O4 (2.5mg/mL) reduced MEK2 expression by 50% (72hr) without rebound; expression of a‐tubulin (control) was unaffected. In contrast, as MEK2 levels decreased, TFR levels increased 2.2‐fold (72hrs). TF‐dpFe3O4 nanoparticles are safe/efficient vehicles for delivering siRNA to cancer cells over‐expressing TFR. Over 72hrs, protein expression of MEK2 reduced by 50%, a target superior to conventional methods. Notably: as the MAPK pathway was inhibited, increases in TFR levels were observed, suggesting adaptations to damage or stress. TF‐dpFe3O4 nanoparticles are a safe and efficient vehicle for delivering siRNA to cancer cells over‐expressing TFR, allowing for successful targeting and inhibition of MAPK pathway proteins, such as MEK2, that drive tumour growth.